Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> CD11b (Cell Surface Glycoprotein MAC1 Alpha Subunit, Complement Component Receptor 3 Alpha, CR3A, ITGAM, MAC1A, MO1A, Neutrophil Adherence Receptor) (FITC)

CD11b (Cell Surface Glycoprotein MAC1 Alpha Subunit, Complement Component Receptor 3 Alpha, CR3A, ITGAM, MAC1A, MO1A, Neutrophil Adherence Receptor) (FITC)

Imprimer Imprimer
Identifiez-vous

Référence C2262-36R-FITC-100ul

Conditionnement : 100ul

Marque : US Biological

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

C2262-36R-FITCCD11b (Cell Surface Glycoprotein MAC1 Alpha Subunit, Complement Component Receptor 3 Alpha, CR3A, ITGAM, MAC1A, MO1A, Neutrophil Adherence Receptor) (FITC)

Specifications
Clone TypeMonoclonal
Hostmouse
Sourcehuman
Swiss ProtP11215
IsotypeIgG1
GradeAffinity Purified
ApplicationsIHC IP
CrossreactivityHu Mk
Shipping TempBlue Ice
Storage Temp-20°C

CD11b cell surface glycoprotein is a 165kD molecule also known as the alphaM integrin, MAC-1 and CR3. This molecule is expressed as a heterodimer in association with the beta 2 integrin, and is found upon monocytes, granulocytes, NK cells and some peripheral blood lymphocytes.

Applications:
Suitable for use in Flow Cytometry, Immunohistochemistry and Immunoprecipitation. Other applications not tested.

Recommended Dilutions:
Flow Cytometry: 1:10-1:100; 10ul labels 10e6 cells or 100ul whole blood.
Immunohistochemistry (Frozen): 1:100-1000
Optimal dilutions to be determined by the researcher.

Hybridoma:
Sp2/0 myeloma cells with spleen cells from Balb/c mice.

Positive Control Tissue:
Human Tosil

Storage and Stability:
Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer.
Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Note: Applications are based on unconjugated antibody.

Applications
Product Type: Mab|Isotype: IgG1|Clone No: ICRF44|Host: mouse|Source: human|Concentration: As Reported|Form: Supplied as a liquid in PBS, pH 7.2. Labeled with Fluorescein isothiocyanate (FITC).|Purity: Purified by Protein G affinity chromatography from tissue culture supernatant.|Immunogen: Rheumatoid synovial cells and human monocytes.|Specificity: Recognizes human CD11b. Species Crossreactivity: Cynomolgus monkey, baboon, Rhesus monkey. Does not react with feline. Reported to have various functional effects on monocytes, blocking adhesion and stimulating cytokine and chemokine release||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Rheumatoid synovial cells and human monocytes.
Form
Supplied as a liquid in PBS, pH 7.2. Labeled with Fluorescein isothiocyanate (FITC).
Purity
Purified by Protein G affinity chromatography from tissue culture supernatant.
Specificity
Recognizes human CD11b. Species Crossreactivity: Cynomolgus monkey, baboon, Rhesus monkey. Does not react with feline. Reported to have various functional effects on monocytes, blocking adhesion and stimulating cytokine and chemokine release
References
1. Yoshino, M. et al. (2000) Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies. Exp. Anim. 49 (2): 97-110. 2. Jonker, M. et al. (1989) Reactivity of mAb specific for human CD markers with Rhesus monkey leucocyte. Leukocyte Typing IV. Oxford University Press 1058-1063. 3. Dransfield, I. et al. (1992) Interaction of leukocyte integrins with ligand is necessary but not sufficient for function. J. Cell Biol. 116: 1527-1535. 4. Malhotra, V. et al. (1986) Ligand binding by the p150,95 antigen of U937 monocytic cells: properties in common with complement receptor type 3 (CR3). Eur. J. Immunol. 16: 1117-1123. 5. Glasow, A. et al. (2005) Retinoids and myelomonocytic growth factors co-operatively activate RAR{alpha} and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 105: 341-9. 6. Rezzonico, R. et al. (2001) Ligation of CD11b and CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta production in primary human monocytes through a pathway dependent on nuclear factor-kappaB. Blood 97: 2932-2940. 7. Rezzonico, R. et al. (2000) Engagement of CD11b and CD11c beta2 integrin by antibodies or soluble CD23 induces IL-1beta production on primary human monocytes through mitogen-activated protein kinase-dependent pathways. Blood 95: 3868-3877. 8. Canalli, A.A. et al. (2001) Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica. 96: 526-33. 9. Patel, S. et al. (2009) Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol. 53: 962-71. 10. Stirling, R.G. et al. (2001) Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 164: 1403-9. 11. Urquhart, P. et al. (2007) Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. J Pharmacol Exp Ther. 321: 656-62. 12. Woollard, K.J. et al. (2002) Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol. 130: 256-62. 13. Ramacciotti, E. et al. (2011) Evaluation of soluble p-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost. 17: 425-31.